Download PDF
Semin Thromb Hemost 2024; 50(01): 034-042
DOI: 10.1055/s-0043-1761217
Review Article

The History of Factor XIII Deficiency

Akbar Dorgalaleh
1   Hamin Tis Research Institute, Tehran, Iran
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Despite the early discovery of factor XIII (FXIII) in 1944, the diagnosis of FXIII deficiency was not made until 1960, after all the other coagulation factor deficiencies, most likely due to the normality of routine coagulation testing in FXIII deficiency. Although the first case was detected by the clot solubility test and this test has long since been used to detect FXIII deficiency, the test is no longer recommended by experts. Over the past 60 years, knowledge about FXIII deficiency has expanded considerably, between 1992, when the first variant was identified, and 2022, 197 mutations have been reported. Almost all missense mutations have a similar effect on FXIII, leading to instability and faster degradation of mutant FXIII protein. Therapeutic options have evolved from historical fresh frozen plasma (FFP), old plasma, whole blood, and cryoprecipitate, to plasma-derived and recombinant FXIII concentrates, respectively available since 1993 and 2012. These concentrate products were respectively approved by the Food and Drug Administration in 2011 and 2013. This historical review covers various aspects of FXIII related disorders, including the discovery of the FXIII, associated disorders, molecular basis, diagnosis, and treatment of FXIII deficiency.

Keywords

factor XIII deficiency - factor XIII - bleeding - diagnosis - management


Publication History

Article published online:
27 January 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Dorgalaleh A, Rashidpanah J. Blood coagulation factor XIII and factor XIII deficiency. Blood Rev 2016; 30 (06) 461-475
    CrossrefPubMedGoogle Scholar
  • 2 Muszbek L, Katona É. Diagnosis and management of congenital and acquired FXIII deficiencies. Semin Thromb Hemost 2016; 42 (04) 429-439
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Girolami A, Cosi E, Ferrari S, Girolami B, Lombardi AM. Bleeding manifestations in heterozygotes with congenital FVII deficiency: a comparison with unaffected family members during a long observation period. Hematology 2017; 22 (06) 375-379
    CrossrefPubMedGoogle Scholar
  • 4 Robbins KC. A study on the conversion of fibrinogen to fibrin. Am J Physiol 1944; 142 (04) 581-588
    CrossrefPubMedGoogle Scholar
  • 5 Duckert F, Jung E, Shmerling DH. A hitherto undescribed congenital haemorrhagic diathesis probably due to fibrin stabilizing factor deficiency. Thromb Diath Haemorrh 1960; 5 (02) 179-186
    PubMedGoogle Scholar
  • 6 Douglas S. Coagulation history, Oxford 1951-53. Br J Haematol 1999; 107 (01) 22-32
    CrossrefPubMedGoogle Scholar
  • 7 Pieters M, Wolberg AS. Fibrinogen and fibrin: an illustrated review. Res Pract Thromb Haemost 2019; 3 (02) 161-172
    CrossrefPubMedGoogle Scholar
  • 8 Larsen JB, Hvas AM. Thrombin: a pivotal player in hemostasis and beyond. Semin Thromb Hemost 2021; 47 (07) 759-774
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Owren PA. Parahaemophilia; haemorrhagic diathesis due to absence of a previously unknown clotting factor. Lancet 1947; 1 (6449): 446-448
    PubMedGoogle Scholar
  • 10 De Vries A, Alexander B, Goldstein R, Addelson E, Promisel E. A factor in serum which accelerates the conversion of prothrombin to thrombin; its determination and some physiologic and biochemical properties. Blood 1949; 4 (03) 247-258
    CrossrefPubMedGoogle Scholar
  • 11 Patek AJ, Stetson RP, Hemophilia I. The abnormal coagulation of the blood and its relation to the blood platelets. J Clin Invest 1936; 15 (05) 531-542
    CrossrefPubMedGoogle Scholar
  • 12 Biggs R, Douglas AS, MacFarlane RG, Dacie JV, Pitney WR. Merskey. Christmas disease: a condition previously mistaken for haemophilia. BMJ 1952; 2 (4799): 1378-1382
    CrossrefPubMedGoogle Scholar
  • 13 Aggeler PM, White SG, Glendenning MB, Page EW, Leake TB, Bates G. Plasman thromboplastin compliment (PTC) deficiency: a new disease resembling hemophilia. Exp Biol Med 1952; 278 (51) 50819-50832
    PubMedGoogle Scholar
  • 14 Telfer TP, Denson KW, Wright DRA. A new coagulation defect. Br J Haematol 1956; 2 (03) 308-316
    CrossrefPubMedGoogle Scholar
  • 15 Denson KW. Electrophoretic studies of the Prower factor; a blood coagulation factor which differs from factor VII. Br J Haematol 1958; 4 (03) 313-325
    CrossrefPubMedGoogle Scholar
  • 16 Graham JB, Hougie C. The Stuart factor (hypoproconvertinemia?). The clotting defect and mode of inheritance. Paper presented at: Proceedings of the International Society of Hematologists, p. 327, vrth Congress, Boston; 1956
    PubMed
  • 17 Rosenthal RL, Dreskin OH, Rosenthal N. New hemophilia-like disease caused by deficiency of a third plasma thromboplastin factor. Proc Soc Exp Biol Med 1953; 82 (01) 171-174
    CrossrefPubMedGoogle Scholar
  • 18 Ratnoff OD, Colopy JE. A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J Clin Invest 1955; 34 (04) 602-613
    CrossrefPubMedGoogle Scholar
  • 19 Dorgalaleh A, Tabibian S, Shams M, Majid G, Naderi M, Casini A. eds. A unique factor XIII mutation in southeastern Iran with an unexpectedly high prevalence: Khash factor XIII. Semin Thromb Hemost 2019; 45 (01) 043-049
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Kohler HP, Ichinose A, Seitz R, Ariens RA, Muszbek L. Factor XIII And Fibrinogen SSC Subcommittee Of The ISTH. Diagnosis and classification of factor XIII deficiencies. J Thromb Haemost 2011; 9 (07) 1404-1406
    CrossrefPubMedGoogle Scholar
  • 21 Naderi M, Dorgalaleh A, Alizadeh S. et al. Clinical manifestations and management of life-threatening bleeding in the largest group of patients with severe factor XIII deficiency. Int J Hematol 2014; 100 (05) 443-449
    CrossrefPubMedGoogle Scholar
  • 22 Dorgalaleh A, Naderi M, Shamsizadeh M. Morbidity and mortality in a large number of Iranian patients with severe congenital factor XIII deficiency. Ann Hematol 2016; 95 (03) 451-455
    CrossrefPubMedGoogle Scholar
  • 23 Board PG, Losowsky MS, Miloszewski KJ. Factor XIII: inherited and acquired deficiency. Blood Rev 1993; 7 (04) 229-242
    CrossrefPubMedGoogle Scholar
  • 24 Duckert F. The fibrin stabilizing factor, factor XIII. Blut 1973; 26 (03) 177-179
    CrossrefPubMedGoogle Scholar
  • 25 Losowsky MS, Miloszewski KJ. Factor XIII. Br J Haematol 1977; 37 (01) 1-5
    CrossrefPubMedGoogle Scholar
  • 26 Giangrande PL. Six characters in search of an author: the history of the nomenclature of coagulation factors. Br J Haematol 2003; 121 (05) 703-712
    CrossrefPubMedGoogle Scholar
  • 27 Laki K, Lóránd L. On the solubility of fibrin clots. Science 1948; 108 (2802): 280-285
    CrossrefPubMedGoogle Scholar
  • 28 Lorand L, Dickenman RC. Assay method for the fibrin-stabilizing factor. Proc Soc Exp Biol Med 1955; 89 (01) 45-48
    CrossrefPubMedGoogle Scholar
  • 29 Duckert F. Documentation of the plasma factor XIII deficiency in man. Ann N Y Acad Sci 1972; 202 (01) 190-199
    CrossrefPubMedGoogle Scholar
  • 30 Saito M, Asakura H, Yoshida T. et al. A familial factor XIII subunit B deficiency. Br J Haematol 1990; 74 (03) 290-294
    CrossrefPubMedGoogle Scholar
  • 31 Girolami A, Cappellato MG, Vicarioto MA. Congenital factor XIII deficiency: type I and type II disease. Br J Haematol 1985; 60 (02) 375-377
    CrossrefPubMedGoogle Scholar
  • 32 Board P, Coggan M, Miloszewski K. Identification of a point mutation in factor XIII A subunit deficiency. Blood 1992; 80 (04) 937-941
    CrossrefPubMedGoogle Scholar
  • 33 Kangsadalampai S, Chelvanayagam G, Baker RT. et al. A novel Asn344 deletion in the core domain of coagulation factor XIII A subunit: its effects on protein structure and function. Blood 1998; 92 (02) 481-487
    CrossrefPubMedGoogle Scholar
  • 34 Board PG, Coggan M, Hamer JW. An electrophoretic and quantitative analysis of coagulation factor XIII in normal and deficient subjects. Br J Haematol 1980; 45 (04) 633-640
    CrossrefPubMedGoogle Scholar
  • 35 Castle S, Board PG, Anderson RAM. Genetic heterogeneity of factor XIII deficiency: first description of unstable A subunits. Br J Haematol 1981; 48 (02) 337-342
    CrossrefPubMedGoogle Scholar
  • 36 Kamura T, Okamura T, Murakawa M. et al. Deficiency of coagulation factor XIII A subunit caused by the dinucleotide deletion at the 5′ end of exon III. J Clin Invest 1992; 90 (02) 315-319
    CrossrefPubMedGoogle Scholar
  • 37 Schroeder V, Meili E, Cung T, Schmutz P, Kohler HP. Characterisation of six novel A-subunit mutations leading to congenital factor XIII deficiency and molecular analysis of the first diagnosed patient with this rare bleeding disorder. Thromb Haemost 2006; 95 (01) 77-84
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Dorgalaleh A, Bahraini M, Shams M. et al. Molecular basis of rare congenital bleeding disorders. Blood Rev 2022; 9: 101029
    CrossrefPubMedGoogle Scholar
  • 39 Bishop PD, Teller DC, Smith RA, Lasser GW, Gilbert T, Seale RL. Expression, purification, and characterization of human factor XIII in Saccharomyces cerevisiae . Biochemistry 1990; 29 (07) 1861-1869
    CrossrefPubMedGoogle Scholar
  • 40 Muszbek L, Bereczky Z, Bagoly Z, Komáromi I, Katona É. Factor XIII: a coagulation factor with multiple plasmatic and cellular functions. Physiol Rev 2011; 91 (03) 931-972
    CrossrefPubMedGoogle Scholar
  • 41 Souri M, Ichinose A. Impaired protein folding, dimer formation, and heterotetramer assembly cause intra- and extracellular instability of a Y283C mutant of the A subunit for coagulation factor XIII. Biochemistry 2001; 40 (45) 13413-13420
    CrossrefPubMedGoogle Scholar
  • 42 Zhang WG, Souri M, Ichinose A. Proteosomal degradation of naturally recurring R260C missense and exon-IV deletion mutants of factor XIII A-subunit expressed in mammalian cells. Haemophilia 2013; 19 (03) 415-419
    CrossrefPubMedGoogle Scholar
  • 43 Coggan M, Baker R, Miloszewski K, Woodfield G, Board P. Mutations causing coagulation factor XIII subunit A deficiency: characterization of the mutant proteins after expression in yeast. Blood 1995; 85 (09) 2455-2460
    CrossrefPubMedGoogle Scholar
  • 44 Vysokovsky A, Rosenberg N, Dardik R, Seligsohn U, Inbal A. Effect of four missense mutations in the factor XIII A-subunit gene on protein stability: studies with recombinant proteins. Blood Coagul Fibrinolysis 2006; 17 (02) 125-130
    CrossrefPubMedGoogle Scholar
  • 45 Takahashi N, Tsukamoto H, Umeyama H, Castaman G, Rodeghiero F, Ichinose A. Molecular mechanisms of type II factor XIII deficiency: novel Gly562-Arg mutation and C-terminal truncation of the A subunit cause factor XIII deficiency as characterized in a mammalian expression system. Blood 1998; 91 (08) 2830-2838
    CrossrefPubMedGoogle Scholar
  • 46 Maeda S, Zhang WG, Souri M, Yee VC, Ichinose A. Impaired dimer assembly and decreased stability of naturally recurring R260C mutant A subunit for coagulation factor XIII. J Biochem 2012; 152 (05) 471-478
    CrossrefPubMedGoogle Scholar
  • 47 Hashiguchi T, Ichinose A. Molecular and cellular basis of deficiency of the b subunit for factor XIII secondary to a Cys430-Phe mutation in the seventh Sushi domain. J Clin Invest 1995; 95 (03) 1002-1008
    CrossrefPubMedGoogle Scholar
  • 48 Mikkola H, Muszbek L, Haramura G, Hämäläinen E, Jalanko A, Palotie A. Molecular mechanisms of mutations in factor XIII A-subunit deficiency: in vitro expression in COS-cells demonstrates intracellular degradation of the mutant proteins. Thromb Haemost 1997; 77 (06) 1068-1072
    Article in Thieme ConnectPubMedGoogle Scholar
  • 49 Sabo TM, Brasher PB, Maurer MC. Perturbations in factor XIII resulting from activation and inhibition examined by solution based methods and detected by MALDI-TOF MS. Biochemistry 2007; 46 (35) 10089-10101
    CrossrefPubMedGoogle Scholar
  • 50 Board PG. Genetic polymorphism of the A subunit of human coagulation factor XIII. Am J Hum Genet 1979; 31 (02) 116-124
    PubMedGoogle Scholar
  • 51 Board PG. Genetic polymorphism of the B subunit of human coagulation factor XIII. Am J Hum Genet 1980; 32 (03) 348-353
    PubMedGoogle Scholar
  • 52 Castle SL, Board PG. An extended survey of the genetic polymorphism at the human coagulation factor XIII: a subunit structural locus. Hum Hered 1985; 35 (02) 101-106
    CrossrefPubMedGoogle Scholar
  • 53 Ichinose A, Davie EW. Characterization of the gene for the subunit of human factor XIII (plasma transglutaminase), a blood coagulation factor. Proc Natl Acad Sci U S A 1988; 85 (16) 5829-5833
    CrossrefPubMedGoogle Scholar
  • 54 Mikkola H, Syrjälä M, Rasi V. et al. Deficiency in the A-subunit of coagulation factor XIII: two novel point mutations demonstrate different effects on transcript levels. Blood 1994; 84 (02) 517-525
    CrossrefPubMedGoogle Scholar
  • 55 Ichinose A, Hendrickson LE, Fujikawa K, Davie EW. Amino acid sequence of the a subunit of human factor XIII. Biochemistry 1986; 25 (22) 6900-6906
    CrossrefPubMedGoogle Scholar
  • 56 Takagi T, Doolittle RF. Amino acid sequence studies on factor XIII and the peptide released during its activation by thrombin. Biochemistry 1974; 13 (04) 750-756
    CrossrefPubMedGoogle Scholar
  • 57 Nakamura S, Iwanaga S, Suzuki T, Mikuni Y, Konishi K. Amino acid sequence of the peptide released from bovine factor XIII following activation by thrombin. Biochem Biophys Res Commun 1974; 58 (01) 250-256
    CrossrefPubMedGoogle Scholar
  • 58 Kohler HP, Stickland MH, Ossei-Gerning N, Carter A, Mikkola H, Grant PJ. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost 1998; 79 (01) 8-13
    Article in Thieme ConnectPubMedGoogle Scholar
  • 59 Vokó Z, Bereczky Z, Katona E, Adány R, Muszbek L. Factor XIII Val34Leu variant protects against coronary artery disease. A meta-analysis. Thromb Haemost 2007; 97 (03) 458-463
    Article in Thieme ConnectPubMedGoogle Scholar
  • 60 Ryan AW, Hughes DA, Tang K. et al. Natural selection and the molecular basis of electrophoretic variation at the coagulation F13B locus. Eur J Hum Genet 2009; 17 (02) 219-227
    CrossrefPubMedGoogle Scholar
  • 61 Fisher S, Rikover M, Naor S. Factor 13 deficiency with severe hemorrhagic diathesis. Blood 1966; 28 (01) 34-39
    CrossrefPubMedGoogle Scholar
  • 62 Seitz R, Duckert F, Lopaciuk S, Muszbek L, Rodeghiero F, Seligsohn U. Study Group. ETRO Working Party on Factor XIII questionnaire on congenital factor XIII deficiency in Europe: status and perspectives. Semin Thromb Hemost 1996; 22 (05) 415-418
    Article in Thieme ConnectPubMedGoogle Scholar
  • 63 Lak M, Peyvandi F, Ali Sharifian A, Karimi K, Mannucci PM. Pattern of symptoms in 93 Iranian patients with severe factor XIII deficiency. J Thromb Haemost 2003; 1 (08) 1852-1853
    CrossrefPubMedGoogle Scholar
  • 64 Shetty S, Shelar T, Mirgal D. et al. Rare coagulation factor deficiencies: a countrywide screening data from India. Haemophilia 2014; 20 (04) 575-581
    CrossrefPubMedGoogle Scholar
  • 65 Ivaskevicius V, Seitz R, Kohler HP. et al; Study Group. International registry on factor XIII deficiency: a basis formed mostly on European data. Thromb Haemost 2007; 97 (06) 914-921
    Article in Thieme ConnectPubMedGoogle Scholar
  • 66 Egbring R, Seitz R, Gürten GV, Köther M, Barthels M, Fuchs G. Bleeding complications in heterozygotes with congenital factor XIII deficiency. In: Mosesson MW, ed. Fibrinogen—Biochemistry, Biological Functions, Gene Regulation and Expression. Amsterdam: Elsevier; 1988. 3. 341-346
    Google Scholar
  • 67 Biswas A, Ivaskevicius V, Thomas A. et al. Eight novel F13A1 gene missense mutations in patients with mild FXIII deficiency: in silico analysis suggests changes in FXIII-A subunit structure/function. Ann Hematol 2014; 93 (10) 1665-1676
    CrossrefPubMedGoogle Scholar
  • 68 Lorand L. Factor XIII: structure, activation, and interactions with fibrinogen and fibrin. Ann N Y Acad Sci 2001; 936 (01) 291-311
    CrossrefPubMedGoogle Scholar
  • 69 Meissner IE. WÖhlisch. Untersuchungen über die Einwirkung hydrotroper Substanzen auf das Fibrinogen und die Blutgerinnung. Biochem Z 1937; 293: 133-141
    PubMedGoogle Scholar
  • 70 Limbourg P. Ueber Lösung und Fällung von Eiweisskörpern durch Salze. Hoppe-Seyler's Zeit. Physiol Chem 1889; 13: 450-463
    PubMedGoogle Scholar
  • 71 Lorand L, Urayama T, De Kiewiet JW, Nossel HL. Diagnostic and genetic studies on fibrin-stabilizing factor with a new assay based on amine incorporation. J Clin Invest 1969; 48 (06) 1054-1064
    CrossrefPubMedGoogle Scholar
  • 72 Dvilansky A, Britten AFH, Loewy AG. Factor XIII assay by an isotope method. I. Factor XIII (transamidase) in plasma, serum, leucocytes, erythrocytes and platelets and evaluation of screening tests of clot solubility. Br J Haematol 1970; 18 (04) 399-410
    PubMedGoogle Scholar
  • 73 Lorand L, Campbell-Wilkes LK, Cooperstein L. A filter paper assay for transamidating enzymes using radioactive amine substrates. Anal Biochem 1972; 50 (02) 623-631
    CrossrefPubMedGoogle Scholar
  • 74 Lee KN, Birckbichler PJ, Patterson Jr MK. Colorimetric assay of blood coagulation factor XIII in plasma. Clin Chem 1988; 34 (05) 906-910
    CrossrefPubMedGoogle Scholar
  • 75 Song YC, Sheng D, Taubenfeld SM, Matsueda GR. A microtiter assay for factor XIII using fibrinogen and biotinylcadaverine as substrates. Anal Biochem 1994; 223 (01) 88-92
    CrossrefPubMedGoogle Scholar
  • 76 Wenzel E, Christ G. Untersuchungen uber die Entstehung von Ammoniak im Zitratplasma nach Rekalzifizierung. Thromb Haemost 1969; 22 (06) 575-576
    PubMedGoogle Scholar
  • 77 Muszbek L, Polgár J, Fésüs L. Kinetic determination of blood coagulation Factor XIII in plasma. Clin Chem 1985; 31 (01) 35-40
    CrossrefPubMedGoogle Scholar
  • 78 Hellstern P, Schilz K, von Blohn G, Wenzel E. Determination of factor XIII activity and of factor XIII inhibitors using an ammonium-sensitive electrode. Thromb Haemost 1983; 50 (02) 563-566
    Article in Thieme ConnectPubMedGoogle Scholar
  • 79 Mousli S, Wakid NW. Ammonia production during clot retraction and its use in assay of fibrinoligase. Clin Chem 1977; 23 (09) 1739-1743
    CrossrefPubMedGoogle Scholar
  • 80 Muszbek L, Polgár J, Fésüs L. Kinetic determination of blood coagulation Factor XIII in plasma. Clin Chem 1985; 31 (01) 35-40
    CrossrefPubMedGoogle Scholar
  • 81 Raut S, Merton RE, Rigsby P. et al; ISTH/SSC Factor XIII Subcommittee and the Factor XIII Standardization Working Party. A collaborative study to establish the 1st International Standard for factor XIII plasma. J Thromb Haemost 2007; 5 (09) 1923-1929
    CrossrefPubMedGoogle Scholar
  • 82 Raut S, Katona É, Riches-Duit A. et al. An international collaborative study to assign value for Total Factor XIII-B Subunit Antigen to the WHO 1st International Standard for Factor XIII Plasma, (02/206): communication from the ISTH SSC subcommittee on factor XIII and fibrinogen. J Thromb Haemost 2022; 20 (02) 525-531
    CrossrefPubMedGoogle Scholar
  • 83 Fadoo Z, Merchant Q, Rehman KA. New developments in the management of congenital Factor XIII deficiency. J Blood Med 2013; 4: 65-73
    CrossrefPubMedGoogle Scholar
  • 84 Gregory TF, Cooper B. Case report of an acquired factor XIII inhibitor: diagnosis and management. Proc Bayl Univ Med Cent 2006; 19 (03) 221-223
    CrossrefPubMedGoogle Scholar
  • 85 Naderi M, Eshghi P, Saneei Moghaddam E. et al. Safety of human blood products in rare bleeding disorders in southeast of Iran. Haemophilia 2013; 19 (02) e90-e92
    CrossrefPubMedGoogle Scholar
  • 86 Kobayashi T, Terao T, Kojima T, Takamatsu J, Kamiya T, Saito H. Congenital factor XIII deficiency with treatment of factor XIII concentrate and normal vaginal delivery. Gynecol Obstet Invest 1990; 29 (03) 235-238
    CrossrefPubMedGoogle Scholar
  • 87 Egbring R, Andrassy K, Havemann K. et al. Longtime therapy of congenital factor XIII deficiency using factor XIII concentrate. Blut 1976; 33 (06) 367-376
    PubMedGoogle Scholar
  • 88 Egbring R, Kröniger A, Seitz R. Factor XIII deficiency: pathogenic mechanisms and clinical significance. Semin Thromb Hemost 1996; 22 (05) 419-425
    Article in Thieme ConnectPubMedGoogle Scholar
  • 89 Kuratsuji T, Oikawa T, Fukumoto T. et al. Factor XIII deficiency in antibiotic-associated pseudomembranous colitis and its treatment with factor XIII concentrate. Haemostasis 1982; 11 (04) 229-234
    PubMedGoogle Scholar
  • 90 Anwar R, Miloszewski KJ. Factor XIII deficiency. Br J Haematol 1999; 107 (03) 468-484
    CrossrefPubMedGoogle Scholar
  • 91 Miloszewski KJ. Safety of long-term prophylaxis in inherited Factor XIII deficiency. In: McDonagh J, Seitz R, Egbring R, eds. Factor XIII. Second International Conference. Marburg, Stuttgart, Germany: F.K. Schattauer Verlagsgesellschaft mbH; 1993: 155-160
    Google Scholar
  • 92 Nugent D. Corifact™/Fibrogammin® P in the prophylactic treatment of hereditary factor XIII deficiency: results of a prospective, multicenter, open-label study. Thromb Res 2012; 130 (2, suppl 2): S12-S14
    CrossrefPubMedGoogle Scholar
  • 93 Kerlin B, Brand B, Inbal A. et al. Pharmacokinetics of recombinant factor XIII at steady state in patients with congenital factor XIII A-subunit deficiency. J Thromb Haemost 2014; 12 (12) 2038-2043
    CrossrefPubMedGoogle Scholar
  • 94 Lovejoy AE, Reynolds TC, Visich JE. et al. Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency. Blood 2006; 108 (01) 57-62
    CrossrefPubMedGoogle Scholar
  • 95 Inbal A, Oldenburg J, Carcao M, Rosholm A, Tehranchi R, Nugent D. Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency. Blood 2012; 119 (22) 5111-5117
    CrossrefPubMedGoogle Scholar
  • 96 Cojutti PG, Zanon E, Pasca S, Pea F. Italian FXIII Study Group. Real-life population pharmacokinetics of recombinant factor XIII and dosing considerations for preventing the risk of bleeding in patients with FXIII congenital deficiency. Clin Pharmacokinet 2022; 61 (04) 505-513
    CrossrefPubMedGoogle Scholar
  • 97 Poulsen LH, Kerlin BA, Castaman G. et al. Safety and effectiveness of recombinant factor XIII-A2 in congenital factor XIII deficiency: real-world evidence. Res Pract Thromb Haemost 2022; 6 (02) e12628
    CrossrefPubMedGoogle Scholar
  • 98 Franchini M, Mannucci PM. The more recent history of hemophilia treatment. Semin Thromb Hemost 2022; 48 (08) 904-910
    Article in Thieme ConnectPubMedGoogle Scholar
  • 99 Chowdary P, Shapiro S, Makris M. et al. Phase 1–2 trial of AAVS3 gene therapy in patients with hemophilia B. N Engl J Med 2022; 387 (03) 237-247
    CrossrefPubMedGoogle Scholar
  • 100 Dorgalaleh A, Kiani J, Zaker F, Safa M. The most common disease-causing mutation of factor XIII deficiency is corrected by CRISPR/CAS9 gene editing system. Blood Coagul Fibrinolysis 2022; 33 (03) 153-158
    CrossrefPubMedGoogle Scholar